The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?
Official Title: Does Physician Education Influence Side Effect Management and Does it Increase Time on Treatment in the Absence of Progression ? A Phase 4 Open-label Trial With Regorafenib in Metastatic Colorectal Cancer
Study ID: NCT02287025
Brief Summary: Randomized trial to evaluate impact of healthcare provider( clinician and nursing staff) support and education on treatment discontinuation rates in the absence of progression in patients with metastatic colorectal cancer treated with regorafenib. Intensified education and support will be provided through an application for iPad which has automatic links to grading, dose reduction and side effect management ,as well as, references for additional articles.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
, Anniston, Alabama, United States
, Anaheim, California, United States
, Orange, California, United States
, Lake City, Florida, United States
, Skokie, Illinois, United States
, Skokie, Illinois, United States
, Lafayette, Indiana, United States
, Columbia, Maryland, United States
, Fayetteville, North Carolina, United States
, Canton, Ohio, United States
, Tulsa, Oklahoma, United States
, Gettysburg, Pennsylvania, United States
, Kingsport, Tennessee, United States
, Houston, Texas, United States
, Tyler, Texas, United States
, Bristol, Virginia, United States
, Portsmouth, Virginia, United States
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR